Melanoma gave science a window into the role immune evasion plays in the development of malignancy. The entire spectrum of immune focused anti-cancer therapies has been subjected to clinical trials in this disease, with limited success until the immune checkpoint blockade era. That revolution launched first in melanoma, heralded a landscape change throughout cancer that continues to reverberate today.
Keywords: CTLA-4; Immune checkpoint; Immunotherapy; Immunotherapy resistance; Immunotherapy response; Melanoma; PD-1; PD-L1.
© 2022. The Author(s), under exclusive license to Springer Nature Switzerland AG.